Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of TIL therapy with high-dose versus low-dose interleukin-2 in metastatic melanoma
2013-001071-20Phase 2Terminated
- Sponsor
- The Christie
- Start
- Sep 2013
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous tumor-infiltrating lymphocytes and aldesleukin in melanoma (2 arms), sponsored by The Christie. Primary endpoint: 3-month objective response rate. Started Sep 2013; status: terminated.
02
Drugs
autologous tumor-infiltrating lymphocytesaldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on 2013-001071-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001071-20.